Companies › Jiangsu Topcel-KH Pharmaceutical
3 active drug programs in 3 registered trials: 2 Phase 1, 1 Phase 3; Oncology, Immunology; next expected readout Dec 2026.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Human TH-SC01 cell injection Umbilical cord-derived allogeneic stem cell therapy | – | Phase 3 | Crohn's Disease | Dec 2026 |
| Anti-PD1 armored CD19 CAR-T cells Anti-PD1 armored CD19 CAR-T cell therapy | CD19, PDCD1 | Phase 1 | Diffuse Large B Cell Lymphoma | Jan 2027 |
| BAFF-R CAR-T cells BAFF receptor-targeted chimeric antigen receptor T-cell therapy | TNFRSF13C | Phase 1 | B-cell Lymphoma | Jan 2027 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06925594 | Human TH-SC01 cell injection | Phase 3 | Crohn's Disease | Immunology | Dec 2026 |
| NCT07368270 | Anti-PD1 armored CD19 CAR-T cells | Phase 1 | Diffuse Large B Cell Lymphoma | Oncology | Jan 2027 |
| NCT07369492 | BAFF-R CAR-T cells | Phase 1 | B-cell Lymphoma | Oncology | Jan 2027 |
Gilead Sciences Bristol-Myers Squibb AstraZeneca Chongqing Precision Biotech Akeso Allogene Therapeutics Amgen Miltenyi Biomedicine Novartis Roche
Beijing Yongtai Ruike Biotechnology Company iCell Gene Therapeutics Hebei Senlang Biotechnology PersonGen BioTherapeutics (Suzhou) Shanghai Ming Ju Biotechnology
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.